论文部分内容阅读
目的研究奥氮平对精神分裂症的临床疗效和安全性。方法对52例精神分裂症患者使用奥氮平治疗6 w，以简明精神病评定量表（BPRS）、阳性症状评定量表（SAPS）、阴性症状评定量表（SANS）与副反应量表（TESS）作为指标，综合评定奥氮平对精神分裂症患者的临床疗效与安全性。结果经过治疗，第3、6 w患者的BPRS、SAPS和SANS均显著低于治疗前（P<0.05），且不良反应较轻。结论奥氮平对精神分裂症临床患者有良好的疗效，安全性高。“,”Objective To investigate the ef ectiveness and safety of Olanzapine tablet on schizophrenia. Methods 52 Schizophrenia patients were treated with Olanzapine for 6 weeks.The value of BPRS,SAPS,SANS and TESS was used to comprehensively evaluate the clinical ef ectiveness and safety of Olanzapine on schizophrenia. Results The value of BPRS, SAPS and SANS after 3-weeks treatment and 6-weeks treatment were al significantly lower than those of pr-treatment (P<0.05) and showed slight adverse ef ects. Conclusion Olanzapine exhibited high ef ectiveness and safety on schizophrenia in clinic.